Alzheimer's Drug Discovery Foundation
| Founder | Leonard A. Lauder, Ronald S. Lauder |
|---|---|
| Focus | Alzheimer's Disease Preclinical Drug Research, Program to Accelerate Clinical Trials, Cognitive Vitality and Prevention, ADDF Access |
| Location |
|
|
Key people
|
Dr. Howard Fillit, Executive Director and Chief Science Officer |
| Slogan | Conquering Alzheimer's Through Drug Discovery |
| Mission | To rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease |
| Website | Official website |
The Alzheimer's Drug Discovery Foundation (ADDF) is a nonprofit organization founded in 1998 by co-chairmen Leonard A. Lauder and Ronald S. Lauder of the Estée Lauder Companies cosmetics family and led by Dr. Howard Fillit, a geriatrician and neuroscientist. The ADDF provides funding to scientists who are conducting promising, innovative Alzheimer's disease drug research worldwide. ADDF funds early-stage research and early-phase clinical trials that might otherwise go unfunded. By supporting research projects around the world, it seeks to increase the chances of finding treatments for Alzheimer's disease, related dementias and cognitive aging ADDF has invested nearly $65 million to fund some 450 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.
The ADDF also publishes peer-reviewed scientific articles with the goal of accelerating and improving Alzheimer's disease drug discovery research.
The ADDF is a biomedical venture philanthropy. Many of its grants are structured as investments, providing a return that is reinvested in new drug research. After initial ADDF funding, grantees have received commitments of over $2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further advance drug research.
Through its programs, the ADDF has invested close to $65 million to fund nearly 450 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries. From 2000 to 2004, the ADDF provided seed funding for Amyvid™, the first FDA-approved diagnostic test for Alzheimer's disease.
The ADDF’s preclinical program funds research focused on translating existing knowledge about the underlying causes of Alzheimer's disease into drug discovery. Areas of research include: neuroprotection, tau-related therapies, ApoE, therapies, mitochondria function and inflammation. In 2013, 69 percent of the ADDF’s drug portfolio was focused on preclinical drug discovery.
...
Wikipedia